Effexor Articles
Reboxetine tops Prozac in head-to-head study
28 May 1999
New indication for AHP's Effexor XR
12 March 1999
Effexor Shows Rapid Onset Of Efficacy Versus Prozac
6 November 1998
Healthy Third-Quarter Growth For US Drug Majors
22 October 1998
American Home Pharma Sales Up 7% For 2nd Qtr
22 July 1998
Merged AHP/Monsanto Will Be Top US Drugmaker
15 June 1998
Scios And Wyeth Terminate Effexor Agreement
7 May 1998
AHP Looks To Bright Future With New Products
30 April 1998
Strong Growth For US Drug Firms In 1997
28 January 1998
Wyeth-Ayerst's Once-Daily Effexor Approved In USA
30 October 1997
US 3rd Quarter Results Show Strong Growth
22 October 1997
Smaller US Firms' Losses Grow Due To R&D Costs
31 July 1997
Solid Growth For US Firms Despite Strong $
24 July 1997
Zoloft Becomes 2nd SSRI Cleared For Panic
23 July 1997
Single-Digit Profits Growth For B-MS And W-L
5 August 1996
Expanding Role Of Venlafaxine
29 July 1996
Effexor Promotion
13 May 1996
Strong Growth At AHP At Start Of 1996
6 May 1996
Antidepressant Growth "Well Above Average"
22 January 1996
US Sales of Generic Drugs Up 29% In 1994, Says IMS
17 July 1995
New Chemical Entities Round-Up For 1994
6 February 1995
Serzone Priced At Discount To SSRIs In USA
16 January 1995
B-MS' Nefazodone: Launch Soon In USA
9 January 1995
Solid 3rd Qtr Growth For Large Pharma Cos
31 October 1994
Effexor Superior To Prozac?
10 October 1994
AHP Bid For Cyanamid Will Broaden Product Range
15 August 1994
NEW PLAYER IN US DEPRESSION MARKET
25 April 1994
RECORD RESULTS FOR AMERICAN HOME
25 April 1994
ROUND-UP OF 1993'S NEW CHEMICAL ENTITIES
31 January 1994
NEW APPROVALS CHANGE DEPRESSION MARKET
17 January 1994
FDA YEAR-END APPROVALS FOR 1993
10 January 1994
EFFEXOR APPROVABLE FOR DEPRESSION
22 November 1993
MURPHY'S LAW PERVADES US DRUG STOCKS
17 May 1993
FDA PANEL BACKS EFFEXOR
10 May 1993
AMERICAN HOME HAS CONFIDENCE FOR 1993
12 April 1993
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
